MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2020003195

Медицинская библиотека · Blood advances · 2021

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Simoes Catia, Paiva Bruno, Martínez-Cuadrón David, Bergua Juan-Miguel, Vives Susana, Algarra Lorenzo, Tormo Mar, Martinez Pilar, Serrano Josefina, Herrera Pilar, Ramos Fernando, Salamero Olga, Lavilla Esperanza, Gil Cristina, Lopez Jose-Luis, Vidriales Maria-Belen, Labrador Jorge, Falantes Jose-Francisco, Sayas María-José, Ayala Rosa, Martinez-Lopez Joaquin, Villar Sara, Calasanz Maria-Jose, Prosper Felipe, San-Miguel Jesús F, Sanz Miguel Ángel, Montesinos Pau

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The value of measurable residual disease (MRD) in elderly patients with acute myeloid leukemia (AML) is inconsistent between those treated with intensive vs hypomethylating drugs, and unknown after semi-intensive therapy. We investigated the role of MRD in refining complete remission (CR) and treatment duration in the phase 3 FLUGAZA clinical trial, which randomized 283 elderly AML patients to induction and consolidation with fludarabine plus cytarabine (FLUGA) vs 5-azacitidine. After consolidation, patients continued treatment if MRD was ≥0.01% or stopped if MRD was <0.01%, as assessed by multidimensional flow cytometry (MFC). On multivariate analysis including genetic risk and treatment arm, MRD status in patients achieving CR (N = 72) was the only independent prognostic factor for relapse-free survival (RFS) (HR, 3.45; P = .002). Achieving undetectable MRD significantly improved RFS of patients with adverse genetics (HR, 0.32; P = .013). Longer overall survival was observed in patients with undetectable MRD after induction though not after consolidation. Although leukemic cells from most patients displayed phenotypic aberrancies vs their normal counterpart (N = 259 of 265), CD34 progenitors from cases with undetectable MRD by MFC carried extensive genetic abnormalities identified by whole-exome sequencing. Interestingly, the number of genetic alterations significantly increased from diagnosis to MRD stages in patients treated with FLUGA vs 5-azacitidine (2.2-fold vs 1.1-fold; P = .001). This study supports MRD assessment to refine CR after semi-intensive therapy or hypomethylating agents, but unveils that improved sensitivity is warranted to individualize treatment and prolong survival of elderly AML patients achieving undetectable MRD.

Для цитирования: Simoes Catia, Paiva Bruno, Martínez-Cuadrón David, Bergua Juan-Miguel, Vives Susana, Algarra Lorenzo, Tormo Mar, Martinez Pilar, Serrano Josefina, Herrera Pilar, Ramos Fernando, Salamero Olga, Lavilla Esperanza, Gil Cristina, Lopez Jose-Luis, Vidriales Maria-Belen, Labrador Jorge, Falantes Jose-Francisco, Sayas María-José, Ayala Rosa, Martinez-Lopez Joaquin, Villar Sara, Calasanz Maria-Jose, Prosper Felipe, San-Miguel Jesús F, Sanz Miguel Ángel, Montesinos Pau. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.. Blood advances. 2021. DOI: 10.1182/bloodadvances.2020003195.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.